Laura E. Niklason

Board Member

CEO

Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.

About Laura E. Niklason

Laura E. Niklason is recorded as Board Member and CEO at Humacyte, Inc. (HUMA). Humacyte, Inc. reported in an 8-K filed June 13, 2024 that Laura E. Niklason was appointed Class III Director, effective June 11, 2024. The proxy statement of Humacyte, Inc. reports total compensation of $5,234,908 for Laura E. Niklason in fiscal 2025, including a base salary of $633,606. Disclosed compensation is on record for 6 fiscal years. Laura E. Niklason has spoken on 1 earnings call across 1 company, most recently for Humacyte, Inc. on August 12, 2026.

“The stockholders elected each of the six Class III directors who were nominated to serve until the Company's 2027 annual meeting of stockholders or until such director's successor is elected, or until such director's earlier death, resignation or removal.”

Humacyte, Inc. Form 8-K, filed June 13, 2024 · Read the filing

Summary generated from SEC filings and earnings-call records held by Equibles.

Research with Equibles

Turn this profile into a cited research brief

Start with a question tailored to the filings and events on this page, or connect Equibles financial data to ChatGPT or Claude.

Suggested question: “Summarize Laura E. Niklason's recent earnings-call comments and cite the source calls.”

Use in your AI

Affiliation history

Recorded current and former roles; source labels appear when available.

Humacyte, Inc. (HUMA)
Board Member

Proxy statement

Current
2024-06-11–present
Humacyte, Inc. (HUMA)
CEO

Proxy statement

Current
2021-08-30–present

Company network

Recorded roles and call appearances connecting this person to public companies.

Humacyte, Inc.

HUMA

Current role

Board Member, CEO

2021-08-30–present

1 appearance Latest appearance 2026-08-12

View calls and events

Leadership on record at Humacyte, Inc.

Other people whose current roles at this company are on record from its filings.

Laura Niklason CEO, Board Member
Dale A. Sander CFO
Dale Sander CFO
Heather Prichard COO
Brady W. Dougan Board Member
C. Bruce Green Board Member
Diane Seimetz Board Member
Emery N. Brown Board Member
John P. Bamforth Board Member
Kathleen Sebelius Board Member

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year	Company	Role	Salary	Bonus	Stock awards	Option awards	Incentive	Other	Total
2025	Humacyte, Inc. (HUMA)	President and Chief Executive Officer	$633,606	$253,983	—	$4,332,725	—	$14,594	$5,234,908
2024	Humacyte, Inc. (HUMA)	President and Chief Executive Officer	$612,400	$278,642	—	—	—	$14,394	$905,436
2023	Humacyte, Inc. (HUMA)	President and Chief Executive Officer	$603,754	$281,704	—	$1,726,450	—	$13,794	$2,625,702
2022	Humacyte, Inc. (HUMA)	President and Chief Executive Officer	$500,000	$212,500	—	$1,031,240	—	$5,348	$1,749,088
2021	Humacyte, Inc. (HUMA)	President and Chief Executive Officer	$500,000	$237,500	—	$10,021,428	—	$44,168	$10,803,096
2020	Humacyte, Inc. (HUMA)	President and Chief Executive Officer	$75,000	—	—	$20,006	—	$106,277	$201,283

Recent activity

Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.

Earnings call Humacyte, Inc. Q2 FY2026 Earnings Call Humacyte, Inc. (HUMA)
2026-08-12
Executive change Appointed: Class III Director Humacyte, Inc. (HUMA)
2024-06-11